PriceTargets.com logo

NASDAQ:ITCI - Intra-Cellular Therapies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $60.43
  • Forecasted Upside: 6.63 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$56.67 As of 05/25/2022 05:00 PM ET
▼ -0.29 (-0.51%)

This chart shows the closing price for ITCI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Intra-Cellular Therapies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ITCI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ITCI

Analyst Price Target is $60.43
▲ +6.63% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Intra-Cellular Therapies in the last 3 months. The average price target is $60.43, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 6.63% upside from the last price of $56.67.

This chart shows the closing price for ITCI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Intra-Cellular Therapies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/22/2022Piper SandlerInitiated CoverageNeutral$59.00High
4/21/2022SVB LeerinkBoost Price TargetOutperform$65.00 ➝ $70.00High
3/2/2022SVB LeerinkBoost Price TargetOutperform$50.00 ➝ $65.00Low
2/25/2022Needham & Company LLCBoost Price TargetBuy$59.00 ➝ $65.00Medium
2/16/2022The Goldman Sachs GroupInitiated CoverageBuy$64.00Low
12/21/2021Royal Bank of CanadaBoost Price TargetOutperform$50.00 ➝ $55.00High
12/20/2021Needham & Company LLCBoost Price TargetBuy$55.00 ➝ $59.00High
12/20/2021SVB LeerinkBoost Price TargetOutperform$45.00 ➝ $50.00High
11/10/2021Royal Bank of CanadaBoost Price TargetOutperform$48.00 ➝ $50.00High
10/27/2021BTIG ResearchReiterated RatingBuy$40.00High
10/24/2021SVB LeerinkReiterated RatingBuyLow
10/21/2021Needham & Company LLCInitiated CoverageBuy$56.00High
10/19/2021Royal Bank of CanadaBoost Price TargetOutperform$44.00 ➝ $48.00High
9/22/2021Needham & Company LLCInitiated CoverageBuy$55.00Medium
9/20/2021Jefferies Financial GroupBoost Price TargetBuy$55.00 ➝ $70.00High
12/29/2020Cantor FitzgeraldBoost Price TargetOverweight$53.00 ➝ $54.00N/A
12/15/2020Bank of AmericaInitiated CoverageBuy$40.00High
12/10/2020The Goldman Sachs GroupInitiated CoverageBuy$38.00High
11/2/2020Royal Bank of CanadaLower Price TargetOutperform$43.00 ➝ $36.00High
11/2/2020BTIG ResearchLower Price TargetBuy$80.00 ➝ $40.00High
9/10/2020Royal Bank of CanadaBoost Price Target$33.00 ➝ $43.00High
9/9/2020BTIG ResearchBoost Price Target$68.00 ➝ $80.00Low
9/9/2020JMP SecuritiesBoost Price TargetOutperform$47.00 ➝ $54.00N/A
3/3/2020BTIG ResearchLower Price TargetBuy$73.00 ➝ $68.00Medium
2/19/2020Evercore ISIInitiated CoverageOutperformMedium
2/18/2020Cantor FitzgeraldReiterated RatingOverweight$43.00 ➝ $47.00High
1/31/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$19.00 ➝ $26.00Low
12/23/2019BTIG ResearchBoost Price TargetBuy$34.00 ➝ $73.00High
9/10/2019SVB LeerinkReiterated RatingBuyLow
9/10/2019JMP SecuritiesSet Price TargetBuy$21.00N/A
9/10/2019Cantor FitzgeraldSet Price TargetBuy$27.00N/A
8/12/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$16.00 ➝ $16.00Low
8/8/2019JMP SecuritiesLower Price TargetMarket Outperform$24.00 ➝ $21.00High
8/7/2019Royal Bank of CanadaSet Price TargetBuy$26.00Low
7/8/2019CowenReiterated RatingBuy$28.00High
5/23/2019Cantor FitzgeraldReiterated RatingOverweight$26.00 ➝ $29.00Medium
5/8/2019Cantor FitzgeraldReiterated RatingBuy$26.00High
4/15/2019Cantor FitzgeraldReiterated RatingBuy$26.00Medium
12/12/2018Royal Bank of CanadaBoost Price TargetOutperform$35.00 ➝ $37.00Low
12/11/2018Cantor FitzgeraldSet Price TargetBuy$32.00High
11/13/2018SVB LeerinkInitiated CoverageOutperform$27.00Medium
11/7/2018Cantor FitzgeraldReiterated RatingBuy$32.00Low
10/23/2018Cantor FitzgeraldSet Price TargetBuy$32.00Low
10/19/2018SVB LeerinkReiterated RatingOutperformHigh
10/4/2018Cantor FitzgeraldReiterated RatingBuy$32.00High
8/23/2018Cantor FitzgeraldInitiated CoverageOverweight$32.00High
8/3/2018Royal Bank of CanadaReiterated RatingBuy$35.00High
8/2/2018Cantor FitzgeraldReiterated RatingBuy$28.00High
7/23/2018Cantor FitzgeraldReiterated RatingBuy$28.00Low
4/3/2018SVB LeerinkSet Price TargetBuy$25.00High
3/4/2018SVB LeerinkReiterated RatingOutperformLow
3/2/2018SunTrust BanksReiterated RatingBuy$28.00Low
3/2/2018CowenReiterated RatingBuy$28.00High
3/1/2018Cantor FitzgeraldReiterated RatingBuy$28.00High
2/26/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$25.00High
2/8/2018Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$33.00Medium
11/8/2017SunTrust BanksUpgradeHold ➝ BuyN/A
9/8/2017BTIG ResearchReiterated RatingBuy$36.00Medium
9/8/2017SunTrust BanksReiterated RatingHold$16.00 ➝ $22.00Low
9/8/2017CowenReiterated RatingOutperform$20.00 ➝ $27.00Medium
9/7/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$14.00 ➝ $33.00High
8/24/2017Piper Jaffray CompaniesSet Price TargetHold$14.00Medium
8/24/2017JMP SecuritiesUpgradeMarket Perform ➝ Outperform$24.00High
8/23/2017CowenReiterated RatingBuy$20.00High
8/23/2017SVB LeerinkUpgradeMarket Perform ➝ OutperformHigh
8/15/2017SVB LeerinkReiterated RatingMarket Perform$12.00Low
8/10/2017Piper Jaffray CompaniesSet Price TargetHold$10.00High
8/9/2017Cantor FitzgeraldReiterated RatingBuyHigh
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/27/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/26/2021
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
12/26/2021
  • 3 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2022
  • 4 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2022

Current Sentiment

  • 4 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Intra-Cellular Therapies logo
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Read More

Today's Range

Now: $56.67
Low: $55.55
High: $56.75

50 Day Range

MA: $58.00
Low: $43.00
High: $65.64

52 Week Range

Now: $56.67
Low: $28.40
High: $66.00

Volume

689,736 shs

Average Volume

1,112,403 shs

Market Capitalization

$5.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Intra-Cellular Therapies?

The following Wall Street research analysts have issued stock ratings on Intra-Cellular Therapies in the last twelve months: BTIG Research, Jefferies Financial Group Inc., Needham & Company LLC, Piper Sandler, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for ITCI.

What is the current price target for Intra-Cellular Therapies?

0 Wall Street analysts have set twelve-month price targets for Intra-Cellular Therapies in the last year. Their average twelve-month price target is $60.43, suggesting a possible upside of 6.6%.
View the latest price targets for ITCI.

What is the current consensus analyst rating for Intra-Cellular Therapies?

Intra-Cellular Therapies currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ITCI will outperform the market and that investors should add to their positions of Intra-Cellular Therapies.
View the latest ratings for ITCI.

How do I contact Intra-Cellular Therapies' investor relations team?

Intra-Cellular Therapies' physical mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company's listed phone number is (464) 440-9333 and its investor relations email address is [email protected] The official website for Intra-Cellular Therapies is www.intracellulartherapies.com. Learn More about contacing Intra-Cellular Therapies investor relations.